Amarantus Bioscience Holdings Inc (AMBS)

[Disney714]

Bristol-Myers Squibb partner to advance Parkinson's disease treatment

Old news but good to read...


http://www.news-medical.net/news/20120921/Vanderbilt-Bristol-Myers-Squibb-partner-to-advance-Parkinsone28099s-disease-treatment.aspx


Vanderbilt University and Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have signed a collaboration agreement
for the discovery, development and commercialization of novel therapies acting on the mGluR4 glutamate receptor, known as positive
allosteric modulators or PAMs, for the treatment of Parkinson's disease.


“The long-term commitment of and collaboration with the MJFF were critical to advancing this program to the stage where it is
now perfectly positioned to work closely with Bristol-Myers Squibb for further development”

Under the collaboration, the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) will identify drug candidates from its
existing program, which obtained major support from The Michael J. Fox Foundation for Parkinson's Research (MJFF).
Bristol-Myers Squibb will have the right to develop and commercialize products resulting from the collaborative research program.

Under the terms of the agreement, Vanderbilt University will receive an upfront payment and multi-year research
funding to continue to discover additional compounds. Vanderbilt is eligible to receive milestones and royalties
based on developmental success and worldwide sales of the drugs emerging from the collaboration.

"The long-term commitment of and collaboration with the MJFF were critical to advancing this program to
the stage where it is now perfectly positioned to work closely with Bristol-Myers Squibb for further development,
" said P. Jeffrey Conn, Ph.D., VCNDD director and Lee E. Limbird, Chair in Pharmacology. "Partnering with Bristol-Myers
Squibb is a real win for Vanderbilt and for Parkinson's patients."


http://en.wikipedia.org/wiki/Metabotropic_glutamate_receptor_4

Metabotropic glutamate receptor 4 is a protein that in humans is encoded by the GRM4 gene.[1][2][3]
Together with GRM6, GRM7 and GRM8 it belongs to group III of the metabotropic glutamate receptor family.
Group III receptors are linked to the inhibition of the cyclic AMP cascade.[3] Activation of GRM4 has potential
therapeutic benefits in the treatment of parkinson's disease. "Taste-GRM4" is involved in the perception of umami.



Bristol-Myers Squibb could do the same thing to Amarantus BioSciences...